Journal of the Neurological Sciences
Volume 203 , Pages 35-39 , 15 November 2002

The costs of vascular dementia: A comparison with Alzheimer's disease

  • Howard Fillit

      Affiliations

    • Corresponding Author InformationCorresponding author. Institute for the Study of Aging, 767 Fifth Ave., Suite 4600, New York, NY 10153, USA. Tel.: +1-212-572-4086.
    • Institute for the Study of Aging, New York, NY 10153, USA
    • Department of Geriatrics and Adult Development, Mount Sinai Medical Center, New York, NY 10032, USA
    • ,
  • Jerrold Hill

      Affiliations

    • Institute for the Study of Aging, New York, NY 10153, USA

References 

  1. Hendrie HC. Epidemiology of dementia and Alzheimer's disease. Am. J. Geriatr. Psychiatry. 1998;6(2):S3–S18
  2. Loeb C. Vascular dementia. Dementia. 1990;1:175–184
  3. Chui H, Victoroff J, Margolin D, Jagust W, Shankel R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42:473–480
  4. Kase C. Epidemiology of multi-infarct dementia. Alzheimer Dis. Assoc. Disord. 1991;5:71–76
  5. Fratiglioni L. Epidemiology. In:  Wimo A,  Jonsson B,  Karlsson G,  Winblad B editor. Health economics of dementia. Chichester: Wiley; 1998;p. 13–31
  6. Erkinjuntti T. Treatment options: the latest evidence with galantamine. In: Second International Congress on Vascular Dementia. 2002; Abstract
  7. Pratt R. Results of clinical studies with donepezil in VaD. In: Second International Congress on Vascular Dementia. 2002; Abstract
  8. Forrette F, Seux M, Staessen J, Thijs L. Antihypertensive treatment prevents dementia: new evidence from the Syst-Eur trial. In: Second International Congress on Vascular Dementia. 2002; Abstract
  9. Tzouria C. The progress study: overall results on stroke and preliminary results on dementia. In: Second International Congress on Vascular Dementia. 2002; Abstract
  10. Gorelick P. Perindopril protection against recurrent stroke study (progress): methodology and overall findings. In: Second International Congress on Vascular Dementia. 2002; Abstract
  11. Meyer J, Rogers R, McClintic K, Mortel K, Lofti J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. J. Am. Geriatr. Soc. 1989;37:549–555
  12. Rashkind M, Peskind E, Wesel T, Yuan W  the Galantamine USA-1 Study Group . Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6 month extension. Neurology. 2000;54:2261–2268
  13. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269–2276
  14. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT  the Donepezil Study Group . A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136–145
  15. Pratt RD. A 54-week, randomized, double-blind, placebo-controlled evaluation of the effects of Donepezil Hydrochloride (E2020) on functional outcomes in patients with Alzheimer's disease. Final Study Report, 54-Week Study on Functional Outcomes. 1999;1–106:9–30
  16. Rosler M, Anand R, Cicin-Sain A, et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BJM. 1999;318:633–640
  17. Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of Rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur. Neurol. 2000;44:236–241
  18. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1265–1266
  19. Hauber AD, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer's disease. PharmacoEconomics. 2000;17(4):351–360
  20. Neumann P, Hermann RC, Kuntz KM, et al.  Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 2000;52:1139–1145
  21. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin. Ther. 1999;21(7):1230–1240
  22. Getsios D, et al.  for the AHEAD Study Group   Assessment of the health economics of Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology. 2001;57:964–971
  23. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am. J. Public Health. 1994;84:1261–1264
  24. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive function and the costs of Alzheimer disease. Arch. Neurol. 1997;54:687–693
  25. Rice D, Fox P, Max W, et al.  The economic burden of Alzheimer's disease care. Health Aff. 1993;14(Summer):164–176
  26. Menzin J, Cummings J, Lang K, Friedman M, Neumann P. The economic cost of Alzheimer's disease and related dementia to the California Medicaid program (Medi-Cal) in 1995. Am. J. Geriatr. Psychiatry. 1999;7(4):300–308
  27. Leon J, Neumann P. The cost of Alzheimer's disease in managed care: a cross-sectional study. Am. J. Manag. Care. 1999;5:867–877
  28. Leon J, Cheng C-K, Neumann P. Alzheimer's disease care: costs and potential savings. Health Aff. 1998;17(6):206–216
  29. Gutterman E, Markowitz J, Lewis B, Fillit HK. Cost of Alzheimer's disease and related dementia in managed-medicare. J. Am. Geriatr. Soc. 1999;47:1065–1071
  30. Taylor D, Sloan FA. How much do persons with Alzheimer's disease cost Medicare?. J. Am. Geriatr. Soc. 2000;48:639–646
  31. Taylor DH, Schenkman M, Zhou J, Sloan FA. The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons. J. Geront., Ser. B Psychol. Sci. Soc. Sci. 2001;56(5):S285–S293
  32. Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H. Alzheimer's disease and related dementias increase costs of comorbidities in managed medicare. Neurology. 2002;58:62–70
  33. Landi F, Gambassi G, Lapne K, Sgadari A, Mor V, Bernabei R. Impact of the type and severity of dementia on hospitalization and survival of the elderly. Dement. Geriatr. Cogn. Disord. 1999;10:121–129
  34. Rockwood K. Societal costs of vascular cognitive impairment in older adults. In: Second International Congress on Vascular Dementia. 2002; Abstract
  35. Fishman P, Von Korff M, Lozano P, Hecht J. Chronic care costs in managed care. Health Aff. 1997;16:239–247
  36. Charlson ME, Pompei P, Ales KI, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987;40:373–382
  37. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 1992;45:613–619
  38. Hachinski V. Multi-infarct dementia: a reappraisal. Alzheimer Dis. Assoc. Disord. 1991;5:64–67
  39. Torian L, Davidson E, Fulop G, et al.  The effect of dementia on acute care in a geriatric medical unit. Int. Psychogeriatr. 1992;4:231–239
  40. Small GW, Donahue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin. Ther. 1998;20(4):838–850
  41. Hill JW, Futterman R, Mastey V, Fillit H. The effect of donepezil therapy on health costs in a medicare managed care plan. Manag. Care Interface. 2001;15(3):63–70
  42. Fillit H, Geldmacher D, Welter R, Maslow K, Malcolm F. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J. Am. Geriatr. Soc. 2002; [In Press]

PII: S0022-510X(02)00257-5

Journal of the Neurological Sciences
Volume 203 , Pages 35-39 , 15 November 2002

Article Tools

* Image Usage & Resolution